Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 2,086 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Open Label Extension Study Clear all

Conditions: Solid Tumors
Interventions: PLX3397, Paclitaxel; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 8
States / cities: Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 5 more

Conditions: Urinary Bladder, Overactive
Interventions: Solifenacin succinate suspension; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Alcohol Dependence, Alcohol Use Disorder
Interventions: XR-NTX+CM (Extended-Release Naltrexone plus Care Management); Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Ulcerative Colitis
Interventions: Mirikizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,058 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 48
States / cities: Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 41 more

Conditions: Bipolar I Disorder
Interventions: Extended-Release Carbamazepine; Drug
Lead sponsor: Validus Pharmaceuticals; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 26
States / cities: Altamonte Springs, Florida • Fort Lauderdale, Florida • Gainesville, Florida + 22 more

Conditions: Moderate to Severe Midface Volume Deficit
Interventions: saypha® VOLUME Lidocaine, Juvéderm® Voluma™ XC; Combination Product
Lead sponsor: Croma-Pharma GmbH; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 562 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 16
States / cities: Scottsdale, Arizona • Encino, California • Fremont, California + 13 more

Conditions: Sexual Dysfunctions, Psychological, Sexual Arousal Disorder
Interventions: sildenafil; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 82
States / cities: Huntsville, Alabama • Anchorage, Alaska • Tucson, Arizona + 68 more

Conditions: Autistic Disorder
Interventions: Kuvan®; Drug
Lead sponsor: The Children's Health Council; Other
Eligibility: 3 Years to 6 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Generalized Myasthenia Gravis
Interventions: Telitacicept, Placebo; Biological · Drug
Lead sponsor: Vor Biopharma; Industry
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 30
States / cities: Scottsdale, Arizona • Los Angeles, California • Orange, California + 26 more

Conditions: Dry Eye Disease (DED)
Interventions: NOV03; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 28
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Glendale, California + 24 more

Conditions: Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Interventions: Inhaled treprostinil solution; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 28
States / cities: Birmingham, Alabama • Sacramento, California • Clearwater, Florida + 23 more

Conditions: Hemostasis, Oral Contraceptive
Interventions: 91-day Levonorgestrel Oral Contraceptive, 28-day Levonorgestrel Oral Contraceptive, 28-day Desogestrel Oral Contraceptive; Drug
Lead sponsor: Teva Women's Health; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 265 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 21
States / cities: San Diego, California • Washington D.C., District of Columbia • Miami, Florida + 16 more

Conditions: Immune Thrombocytopenia
Interventions: Rilzabrutinib, Placebo; Drug
Lead sponsor: Principia Biopharma, a Sanofi Company; Industry
Eligibility: 10 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 17
States / cities: Los Angeles, California • San Francisco, California • Torrance, California + 13 more

Conditions: Parkinson's Disease
Interventions: IPX066 95 mg, IPX066 145 mg, IPX066 195 mg, IPX066 245 mg; Drug
Lead sponsor: Impax Laboratories, LLC; Industry
Eligibility: 30 Years and older
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 30 more

Conditions: Chronic Kidney Disease, Proteinuria, Children
Interventions: Finerenone (Kerendia, BAY94-8862); Drug
Lead sponsor: Bayer; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 18
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 15 more

Conditions: Pediatric Epileptic Syndrome, Partial-onset Seizures
Interventions: Perampanel Oral Suspension, Perampanel Tablet; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 1 Month to 18 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 15
States / cities: Los Angeles, California • Aurora, Colorado • Miami, Florida + 12 more

Conditions: Type 2 Diabetes Mellitus
Interventions: HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 807 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 95
States / cities: Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 78 more

Conditions: Bipolar Depression
Interventions: lurasidone; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 817 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 58
States / cities: Little Rock, Arkansas • Anaheim, California • Chino, California + 49 more

Conditions: Urinary Bladder, Overactive
Interventions: solifenacin succinate; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 441 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 104
States / cities: Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 90 more

Conditions: Hepatic Impairment, Cirrhosis, Cholestatic Liver Disease
Interventions: Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg; Drug
Lead sponsor: Zydus Therapeutics Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Alopecia Areata
Interventions: CTP-543; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 72
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 61 more

Conditions: Focal Onset Seizure
Interventions: Cenobamate; Drug
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 19
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 15 more

Conditions: B-cell Non-Hodgkin Lymphoma
Interventions: DI-Leu16-IL2; Drug
Lead sponsor: Alopexx Oncology, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Duarte, California • Minneapolis, Minnesota • Lebanon, New Hampshire

Conditions: Thyroid Eye Disease
Interventions: Observational cohort study, Batoclimab; Other · Drug
Lead sponsor: Immunovant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 9
States / cities: Glendora, California • Aurora, Colorado • Livonia, Michigan + 6 more

Search by objective public record fields.

Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors

A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076

Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

The Young Adult and Pediatric Bipolar Study

Saypha® VOLUME Lidocaine for Midface Augmentation

An Open-Label, Extension Study Evaluating the Safety, Toleration, and Efficacy of Sildenafil in Women With Sexual Arousal Disorder

Open-Label Extension Study of Kuvan for Autism

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)

Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)

A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women

Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin

Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression

Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder

Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy

Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL

Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease